CN107518411A - A kind of anti-diarrhea enteral nutrition composition - Google Patents
A kind of anti-diarrhea enteral nutrition composition Download PDFInfo
- Publication number
- CN107518411A CN107518411A CN201710022204.9A CN201710022204A CN107518411A CN 107518411 A CN107518411 A CN 107518411A CN 201710022204 A CN201710022204 A CN 201710022204A CN 107518411 A CN107518411 A CN 107518411A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- pectin
- reference examples
- bifidobacterium
- bacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000035764 nutrition Effects 0.000 title claims abstract description 19
- 230000001142 anti-diarrhea Effects 0.000 title description 3
- 229920001277 pectin Polymers 0.000 claims abstract description 99
- 235000010987 pectin Nutrition 0.000 claims abstract description 96
- 239000001814 pectin Substances 0.000 claims abstract description 96
- 230000032050 esterification Effects 0.000 claims abstract description 48
- 238000005886 esterification reaction Methods 0.000 claims abstract description 48
- 239000006041 probiotic Substances 0.000 claims abstract description 35
- 235000018291 probiotics Nutrition 0.000 claims abstract description 35
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 11
- 230000002496 gastric effect Effects 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 210000000936 intestine Anatomy 0.000 claims description 27
- 241000186660 Lactobacillus Species 0.000 claims description 23
- 229940039696 lactobacillus Drugs 0.000 claims description 23
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 19
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 14
- 241000194033 Enterococcus Species 0.000 claims description 14
- 230000001332 colony forming effect Effects 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 241000186429 Propionibacterium Species 0.000 claims description 10
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 10
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 9
- 241001478240 Coccus Species 0.000 claims description 9
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 9
- 241000606125 Bacteroides Species 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 8
- 241000194017 Streptococcus Species 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 7
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 7
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 7
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 6
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 6
- 241001468229 Bifidobacterium thermophilum Species 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 6
- 240000001929 Lactobacillus brevis Species 0.000 claims description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 6
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 6
- 241000228245 Aspergillus niger Species 0.000 claims description 5
- 241000193749 Bacillus coagulans Species 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 5
- 241001608472 Bifidobacterium longum Species 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 244000199866 Lactobacillus casei Species 0.000 claims description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 5
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 5
- 241000191998 Pediococcus acidilactici Species 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 5
- 229940054340 bacillus coagulans Drugs 0.000 claims description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- 241000193798 Aerococcus Species 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 4
- 240000006439 Aspergillus oryzae Species 0.000 claims description 4
- 241000194103 Bacillus pumilus Species 0.000 claims description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 4
- 241000186148 Bifidobacterium pseudolongum Species 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 4
- 241000193171 Clostridium butyricum Species 0.000 claims description 4
- 241000605909 Fusobacterium Species 0.000 claims description 4
- 244000285963 Kluyveromyces fragilis Species 0.000 claims description 4
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 claims description 4
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 4
- 241001134659 Lactobacillus curvatus Species 0.000 claims description 4
- 241000186841 Lactobacillus farciminis Species 0.000 claims description 4
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 4
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 4
- 241000194036 Lactococcus Species 0.000 claims description 4
- 241000192132 Leuconostoc Species 0.000 claims description 4
- 241000192041 Micrococcus Species 0.000 claims description 4
- 241000235395 Mucor Species 0.000 claims description 4
- 241000191996 Pediococcus pentosaceus Species 0.000 claims description 4
- 241000228143 Penicillium Species 0.000 claims description 4
- 241000235648 Pichia Species 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 241000235527 Rhizopus Species 0.000 claims description 4
- 241000606008 Ruminobacter amylophilus Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 241000191965 Staphylococcus carnosus Species 0.000 claims description 4
- 244000057717 Streptococcus lactis Species 0.000 claims description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 4
- 241000194108 Bacillus licheniformis Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 241000726221 Gemma Species 0.000 claims description 3
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 3
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 3
- 241000192001 Pediococcus Species 0.000 claims description 3
- 241000191973 Staphylococcus xylosus Species 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 2
- 241000193422 Bacillus lentus Species 0.000 claims description 2
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- 241000235035 Debaryomyces Species 0.000 claims description 2
- 241000478535 Eleutherodactylus intermedius Species 0.000 claims description 2
- 241000194031 Enterococcus faecium Species 0.000 claims description 2
- 241001106597 Enterococcus lactis Species 0.000 claims description 2
- 241000186715 Lactobacillus alimentarius Species 0.000 claims description 2
- 241000186713 Lactobacillus amylovorus Species 0.000 claims description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 2
- 241000186612 Lactobacillus sakei Species 0.000 claims description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims description 2
- 241001468189 Melissococcus Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 241000202223 Oenococcus Species 0.000 claims description 2
- 241000191992 Peptostreptococcus Species 0.000 claims description 2
- 241000186428 Propionibacterium freudenreichii Species 0.000 claims description 2
- 241001528479 Pseudoflavonifractor capillosus Species 0.000 claims description 2
- 241000235342 Saccharomycetes Species 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 2
- 241000202221 Weissella Species 0.000 claims description 2
- 235000013405 beer Nutrition 0.000 claims description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 2
- 235000013557 nattō Nutrition 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 abstract description 45
- 206010047700 Vomiting Diseases 0.000 abstract description 29
- 206010000060 Abdominal distension Diseases 0.000 abstract description 28
- 230000008673 vomiting Effects 0.000 abstract description 26
- 210000002784 stomach Anatomy 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 206010067484 Adverse reaction Diseases 0.000 description 24
- 230000006838 adverse reaction Effects 0.000 description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 239000011575 calcium Substances 0.000 description 13
- 229910052791 calcium Inorganic materials 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000003292 glue Substances 0.000 description 12
- 235000013399 edible fruits Nutrition 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 7
- 235000013325 dietary fiber Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 150000004671 saturated fatty acids Chemical class 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- -1 galactolipin Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000193395 Sporosarcina pasteurii Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical class OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 208000008279 Dumping Syndrome Diseases 0.000 description 1
- 241000360590 Erythrites Species 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- OKPQBUWBBBNTOV-UHFFFAOYSA-N Kojibiose Natural products COC1OC(O)C(OC2OC(OC)C(O)C(O)C2O)C(O)C1O OKPQBUWBBBNTOV-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- UNXHWFMMPAWVPI-IMJSIDKUSA-N L-threitol Chemical class OC[C@H](O)[C@@H](O)CO UNXHWFMMPAWVPI-IMJSIDKUSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 208000032395 Post gastric surgery syndrome Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001312 aldohexoses Chemical class 0.000 description 1
- 150000001320 aldopentoses Chemical class 0.000 description 1
- 150000001330 aldotetroses Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-BTLHAWITSA-N alpha,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-BTLHAWITSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 1
- 229940085298 biotin 10 mg Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N butane-1,2,3,4-tetrol Chemical compound OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 150000003999 cyclitols Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002454 idoses Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 150000002574 ketohexoses Chemical class 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 150000002586 ketotetroses Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- PZDOWFGHCNHPQD-OQPGPFOOSA-N kojibiose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-OQPGPFOOSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- QIGJYVCQYDKYDW-LCOYTZNXSA-N laminarabiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-LCOYTZNXSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000002671 oral rehydration therapy Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Present invention is disclosed a kind of enteral nutritional composition for reducing gastrointestinal side effect incidence and particularly reducing Incidence of Diarrhea, the enteral nutritional composition includes pectin of one or more esterification degrees less than 50%, one or more probiotics(Viable bacteria)And one or more nutrition compositions, calcium ion is no more than 0.1PPM in the enteral nutritional composition.The enteral nutritional composition can substantially reduce gastrointestinal side effect (such as diarrhoea, abdominal distension, vomiting) and particularly suffer from diarrhoea.
Description
Technical field
The present invention relates to a kind of enteral nutritional composition, is particularly more specifically to a kind of gastrointestinal side effect
The intestines of Incidence of Diarrhea reduction.
Background technology
Enteral nutrition(Enteral Nutrition)Refer to tube feed pipe through side nasal cavity, oral cavity or Gastroenteritic mouth etc.
Stomach or enteral are inserted, essential food or liquid diet are instilled out of pipe, to ensure that patient takes in controlling for enough protein and heat
Treatment method.Elental refers to the general name of the various products for clinical EN support, and rational nutritional support can increase
The resistance of strong body, sb.'s illness took a favorable turn for promotion, it might even be possible to extends patient vitals.But Elental is in clinical practice
There is also many deficiencies being difficult to avoid that in journey, mainly there are gastrointestinal reaction, Nausea and vomiting or abdominal distension, stomachache, diarrhoea etc..
Qian Pingping etc. has found:Apple contains abundant dietary fiber DF, its main component pectin, belongs to soluble dietary fiber
SDF, SDF function help to reduce patient's Incidence of Diarrhea(Apple butter prevents and improved the clinical observation of tube-fed patients' diarrhoea,Chinese Clinical Health Care, the 5th phase of volume 11 lO months in 2008, the 486-487 pages).
Patent CN201380004157.5, which discloses one kind, can thicken enteric nutrient and not produced in preservation
The aqueous pectin solution of precipitation, aqueous pectin solution described in patent contain esterification degree for 5~15%,(It is viscous equal)Molecular weight is 10000
~35000 pectin, the calcium concentration of aqueous pectin solution is below 9ppm, pectin viscosity (25 DEG C) is 1~30mPas.And point out
The aqueous pectin solution 100mL and calcium/sodium water solution that calcium chloride is 0.019mol/L, sodium citrate is 0.020mol/L
The viscosity (25 DEG C) of 200mL mixed liquor is 700~10000mPas.The aqueous pectin solution of the invention, it is not only conventional sodium
Content is below 150mg/100mL enteric nutrient, even the more enteric nutrients of sodium content, especially sodium content are
More than 180mg/100mL enteric nutrient can also make its thickening, and the enteric nutrient that can prevent from giving into stomach falls
Stream, diarrhoea, dumping syndrome.
Patent US6187334 is disclosed containing LM(Esterification degree is less than 50%), sodium alginate, alginic acid,
Kappa carrageenans, iota carrageenans, lambda carrageenans, gellan gum(gellan gum)Antiemetic edible thing.
Patent CN105664170A discloses a kind of good amidated low ester pectin composition of quality stability, the combination
Thing includes(It is viscous equal)The pectin that molecular weight is 70000~150000, acylation degree is 15~30%, esterification degree is 20~35%, the group
Compound thickening effect and gel breaking strength during Clinical practice can more match the combination of pectins of Human Physiology demand, can
To alleviate the adverse reaction problem such as Nausea and vomiting, abdominal distension, stomachache, diarrhoea existing for Elental user.
Use of the probiotics in acute diarrhea is treated, especially viral diarrhoea, Europe and
The U.S. has obtained extensive research.In these researchs, lactobacillus GG, lactobacillus reuteri (1actobacillus
Reuteri), lactobacterium acidophilus (1actobacillus acidophilus Lb), saccharomycete, and a kind of streptococcus thermophilus
(streptococcus thermophilus), lactobacterium acidophilus and Bulgarian lactic acid bacterium (1actobacillus
Bulgaricus combination product) result in the severity of diarrhoea and the reduction of duration, no matter in flourishing or development
Middle country, when using being administered alone or a part as oral rehydration therapy, all with it is such the effect of(Referring to:1).
Van Niel C W, Feudtner C, Garrison M M, et af.Lactobacillus therapy for acute
infectious darrhea in children:A meta-analysis [J] .Pediatrics, 2002,109:
678—684.2).McFarland L V, Elmer G W, Surawicz C M.Breaking the cycle:
Treatment Strategies for l63 cases of recurrent Clostridium difficile disease
[J] American Journal of G astroenterology, 2002,97:1769 l775.3).Szajewska H,
Mrukowicz J z.Probiotics in the treatment and prevention of acute infectious
diarrhea in infants and children:A systematic review of published randomized,
Double blind, placebo controlled trials [J] Journal of Pediatric
Gastroenterology and Nutrition, 2001,33:S17 $25.).
Zhang Liya etc. has found that the senile diarrhoea of prebiotic mattress joint enteral nutrition prevention has good result, securely and reliably(Referring to:
Probiotic combination enteral nutrition prevents the clinical research of senile diarrhoea,Chinese community doctor medical speciality, 2012 the 18th
Phase, the 160-161 pages).
Wang Chuanmei etc. has found that probiotics intervenes the generation that can reduce COPD patient diarrhoea with dislocation of bacillary groups, improves enteral nutrition
Success rate(Referring to:Add the clinical observation for using probiotics enteral nutrition to preventing COPD patient diarrhoea with dislocation of bacillary groups,Clinical lung Section's magazine, the 3rd phase of volume 15 in March, 2010, the 332-333 pages).
However, the gastrointestinal side effect such as above-mentioned Nausea and vomiting or abdominal distension, stomachache, diarrhoea problem is still in the prior art
Exist to a certain extent, also larger room for improvement.
The content of the invention
It is an object of the invention to provide a kind of enteral nutrition of gastrointestinal side effect particularly Incidence of Diarrhea reduction
Composition.
Based on above-mentioned purpose, a person of good sense is unexpectedly upper existing in sheet, and probiotics is added to pectous enteral nutritional composition
In, the incidence that gastrointestinal side effect is particularly suffered from diarrhoea can be reduced, improves the security of the enteral nutritional composition.
Gastrointestinal side effect (such as diarrhoea, abdominal distension, vomiting) incidence, which is reduced, the present invention relates to one kind particularly reduces abdomen
The enteral nutritional composition of incidence is rushed down, the enteral nutritional composition includes pectin of one or more esterification degrees less than 50%, one
Kind or a variety of probiotics(Viable bacteria)And one or more nutrition compositions, calcium ion is no more than in the enteral nutritional composition
0.1PPM.The enteral nutritional composition can substantially reduce gastrointestinal side effect and be particularly abdomen (such as diarrhoea, abdominal distension, vomiting)
Rush down.
For the present invention's(Methoxyl group)Pectin example of the esterification degree less than 50% includes the fruit from cedra fruits
Glue, such as from lemon, blue or green lemon(lime), citrus, grape, the pectin in apple etc..Pectin of the esterification degree less than 50% has stomach and intestine
In can react to form gel antiemetic with calcium ion.
Esterification degree for the present invention is preferred less than 50% pectin(Contain)Esterification degree be 5~30% and(It is viscous equal)Molecular weight
For 10000~150000 pectin, particularly preferably(Contain)Esterification degree (DE) be 5~15% and(It is viscous equal)Molecular weight is
10000~150000 pectin, particularly preferably(Contain)Esterification degree be 5~15 % and(It is viscous equal)Molecular weight be 10000~
50000 pectin, most preferably(Contain)Esterification degree be 5~15 % and(It is viscous equal)Molecular weight is 10000~35000
Pectin.The esterification degree of pectin as little as less than 15% and calcium reactivity is high, and will(It is viscous equal)Molecular-weight adjusting to 10000~
35000th, 12000~27000 are preferably adjusted to.Can be formed when the esterification degree of pectin is too low, when being reacted with calcium ion it is firm not
Solubleness gel, it is undesirable from the point of view of in terms of digesting and assimilating, therefore is more than 5%.It is appropriate viscous from it is thickened to
From the viewpoint of degree, the esterification degree for making pectin is 5~15%, is more preferably 6~13%.When esterification degree is higher than 15% too many, fruit
Glue and calcium ion it is reactive it is low, enteral nutrition composition can not be made fully to thicken.
For pectin of the invention(It is viscous equal)Molecular weight is preferably 10000~35000, more preferably 12000~
27000.Herein,(It is viscous equal)Molecular weight is being averaged of calculating of utilization level viscosimetry(It is viscous equal)Molecular weight.Pectin(It is viscous equal)Point
When son amount is excessive, firm insoluble gel is generated by the reaction with calcium ion, is not from the point of view of in terms of digesting and assimilating
Preferably.From the viewpoint of it is thickened to proper viscosity, make pectin(It is viscous equal)Molecular weight is less than 35000, is preferably
Less than 27000, less than 16000 are more preferably.On the contrary,(It is viscous equal)When molecular weight is too small, pectin and calcium ion it is reactive it is low,
Enteral nutrition composition can not be made fully to thicken, therefore(It is viscous equal)Molecular weight is more than 10000, is preferably more than 12000, more
Preferably more than 14000.In addition, by making pectin(It is viscous equal)Molecular weight is above-mentioned scope, easily by aqueous pectin solution
Viscosity is adjusted to the 30mPas (25 DEG C) for being suitable for giving through pipe below.
Content of pectin of the esterification degree less than 50% in above-mentioned enteral nutritional composition is 0.1~10%(W/w),
Preferably 0.3~5%(W/w), more preferably 0.5~3%(W/w).
But in the enteral nutritional composition of the present invention, the content of pectin can be according to pectin(It is viscous equal)Molecular weight etc. is appropriate
Adjustment is so that the viscosity of aqueous pectin solution reaches above-mentioned scope, for example, in pectin(It is viscous equal)Molecular weight be 10000~
In the case of 35000,1~5 mass % is set to.When the content of pectin is very few, enteral nutrition composition can not be made fully
Thickening, when opposite excessive, firm gel is generated due to the reaction with enteral nutrition composition, therefore from the side digested and assimilated
It is undesirable from the point of view of face.
Suitable probiotics for the present invention(Viable bacteria)Including but not limited to yeast(Bacterium), such as saccharomyces
(Saccharomyces), Debaryomyces (Debaromyces), candida (Candida), pichia category
(Pichia) and Torulopsis (Torulopsis), mould, as aspergillus (Aspergillus), rhizopus (Rhizopus),
Mucor (Mucor), Penicillium (Penicillium) and Torulopsis (Torulopsis), and bacterium, such as Bifidobacterium
Belong to (Bifidobacterium), Clostridium (Clostridium), Fusobacterium (Fusobacterium), honeybee
Coccus (Melissococcus), Propionibacterium (Propionibacterium), streptococcus (Streptococcus),
Enterococcus spp (Enterococcus), lactococcus (Lactococcus), Cook Pseudomonas (Kocuriaw), staphylococcus
(Staphylococcus), Peptostreptococcus (Peptostrepococcus), bacillus (Bacillus), piece coccus
Belong to (Pediococcus), Micrococcus (Micrococcus), Leuconostoc (Leuconostoc), Wei Si Bordetella
(Weissella), Aerococcus (Aerococcus), wine Coccus (Oenococcus) and lactobacillus
(Lactobacillus)。
Preferable probiotics example includes but is not limited to aspergillus niger (Aspergillus niger), aspergillus oryzae
(A.oryzae), bacillus coagulans (Bacillus coagulans), slow bacillus (B.lentus), lichenoid form gemma
It is bacillus (B.licheniformis), goldbeater's skin bacillus (B.mesentericus), bacillus pumilus (B.pumilus), withered
Careless bacillus (B.subtilis), bafillus natto (B.natto), bacteroides amylophilus (Bacteroides
Amylophilus), bacteroides capillosus (Bac.capillosus), the raw bacteroid of cud (Bac.ruminocola), pig bacteroid
(Bac.suis), bifidobacterium adolescentis (Bifidobacterium adolescentis), animal bifidobacteria
(B.animalis), bifidobacterium breve (B.breve), bifidobacterium bifidum (B.bifidum), bifidobacterium infantis
(B.infantis), bifidobacterium lactis (B.lactis), bifidobacterium longum (B.longum), bifidobacterium pseudolongum
(B.pseudolongum), bifidobacterium thermophilum (B.thermophilum), Candida pintolepesii, butyric acid fusiform bud
Spore bacillus (Clostridium butyricum), butterfat enterococcus (Enterococcus cremoris), two butanone enterococcus
(E.diacetylactis), VREF (E.faecium), middle enterococcus (E.intermedius), lactoenterococcus
(E.lactis), E.muntdi, thermophilic enterococcus (E.thermophilus), bacillus coli (Escherichia
Coli), Kluyveromyces fragilis (Kluyveromyces fragilis), lactobacillus acidophilus (Lactobacillus
Acidophilus lactobacillus (L.alimentarius), food starch lactobacillus (L.amylovorus), Lactobacillus crispatus), are digested
(L.crispatus), short and small lactobacillus (L.brevis), Lactobacillus casei (L.case 4), lactobacillus curvatus
(L.curvatus), lactobacillus cellobiosas (L.cellobiosus), lactobacillus delbruockii subspecies bulgaricus
(L.delbrueckii ss.bulgaricus), Lactobacillus farciminis (L.farciminis), lactobacillus fermenti
(L.fermentum), Lactobacillus gasseri (L.gasseri), Lactobacillus helveticus (L.helveticus), lactobacillus lactis
(L.lactis), Lactobacillus plantarum (L.plantarum), Yue Shi lactobacillus (L.johnsonii), lactobacillus reuteri
(L.reuteri), Lactobacillus rhamnosus (L.rhamnosus), Lactobacillus saki (L.sakei), Lactobacillus salivarius
(L.salivarius), mesenterium shape leukonid (Leuconostoc mesenteroides), beer (harmful) piece coccus
(P.cereviseae (damnosus)), Pediococcus acidilactici (Pediococcus acidilactici), Pediococcus pentosaceus
(P.pentosaceus) Roy Deng Shi Propionibacteriums (Propionibacterium freudenreichii), Xue Man Na Shi, are taken
Propionibacterium (Prop.shermanii), Saccharomyces cerevisiae (Saccharomyces cereviseae), Staphylococcus carnosus
(Staphylococcus carnosus), staphylococcus xylosus (Staph.xylosus), baby streptococcus
(Streptococcus in fantarius), saliva chain coccus thermophilous subspecies (Strep.salivarius
Ss.thermophilus), streptococcus thermophilus (Strep.Thermophilus) and streptococcus lactis (Strep.lactis).
Particularly preferred probiotics example includes but is not limited to streptococcus thermophilus, lactobacillus acidophilus (Lactobacillus
Acidophilus), lactobacillus bulgaricus (Lactobacillus bulgaricus), Lactobacillus casei
(Lactobacillus casei), Lactobacillus rhamnosus (Lactobacillus rhamnosus), lactobacillus fermenti
(Lactobacillus fermentum), Lactobacillus salivarius (Lactobacillus salivaroes), Lactobacillus brevis
(Lactobacillus brevis), Lactobacillus plantarum (Lactobacillus plantarum), lactobacillus reuteri
(Lactobacillus ruteri), Bacillus pasteurii (Bacillus pasteurii), streptococcus thermophilus
(Streptococcus thermophilus), production spore bacillus (Bacillus sporogenes), bifidobacterium adolescentis
(Bifidobacterium adolescentis), bifidobacterium infantis (Bifidobacterium infantis), long bifid
Bacillus (Bifidobacterium longum), bifidobacterium thermophilum (Bifidobacterium thermophilus) or bifid
Bifidobacterium (Bifidobacterium bifidum).
It is KB4, KB19 or KB25 bacterial strain that most preferred probiotics example, which includes but is not limited to streptococcus thermophilus,.
A kind of every 100ml content about 1 hundred million to about 2,000 hundred million of any of the above-described probiotics in above-mentioned enteral nutritional composition
Colony forming unit, the colony forming unit of preferably from about 1,000,000,000 to about 100,000,000,000, the colony of more preferably from about 2,000,000,000 to about 50,000,000,000
Form unit.
The nutritional ingredient of the addible needed by human body of enteral nutritional composition of the present invention and suitable additive.
The nutritional ingredient that can include of enteral nutritional composition of the present invention includes amino acid, peptide, protein, monosaccharide and disaccharide,
3 to 20 sugar and their sugar alcohol, the polysaccharide in addition to pectin, vitamin, trace element(Not comprising calcium ion, do not include preferably
Other divalent cations or more high-valence cationic), and their any combination etc..
Above-mentioned addible nutritional ingredient, can include monose as shown below, disaccharides, 3~20 sugar sugar or they
Sugar alcohol.
As monosaccharide, such as the aldotetroses such as erythrose, threose can be included;Ribose, lyxose, xylose, arabinose
Deng aldopentose;The aldohexoses such as allose, talose, gulose, glucose, altrose, mannose, galactolipin, idose;Red moss
The ketotetroses such as ketose;The pentuloses such as xylulose, ribulose;Ketohexoses such as psicose, fructose, sorbose, Tagatose etc..As
Disaccharides, such as the α-diglucoside such as trehalose, kojibiose, nigerose, maltose, isomaltose can be included;Different marine alga
β-the diglucoside such as sugar, sophorose, laminaribiose, cellobiose, gentiobiose;The α such as neotrehalose, β-diglucoside;And breast
Sugar, sucrose, isomaltoketose (palatinose) etc..As three carbohydrates, such as gossypose etc. can be included.It is sugared as trisaccharide~six
Oligosaccharide, such as can to include FOS, galacto-oligosaccharide, xylo-oligosaccharide, oligoisomaltose, chitin oligo saccharide, shell few
Cyclic oligosaccharides such as sugar, oligo-glucosamine, dextrin, cyclodextrin etc..
In addition, the alcohol as monose, such as the tetritol such as erythrite, D- threitols, L- threitols can be included;D- I
The pentitols such as primary sugar alcohol, xylitol;D- iditols, galactitol (dulcitol), D- glucitols (sorbierite), mannitol etc. oneself
Sugar alcohol;Cyclitols such as inositol etc..In addition, as dialditol, such as maltitol, lactitol, isomalt can be included
(isomalt) etc., as the alcohol of oligosaccharide, pentaerythrite, reduction maltose syrups etc. can be included.
As needed, suitable additive includes any conditions such as pH adjusting agent, thickening polysaccharide, stabilizer.
The present invention enteral nutritional composition be further characterized in that, calcium concentration as little as below 9ppm, preferably 4.5ppm with
Under, so as to inhibit enteral nutritional composition to produce precipitation in preservation.
In addition, the pH of the enteral nutritional composition of the present invention is preferably 3~8, more preferably 4~6.5.
(25 DEG C) of the viscosity of the enteral nutritional composition of the present invention is below 30mPas, is preferably below 10mPas.
From the viewpoint of enteral nutrition composition is moderately thickened, the viscosity (25 DEG C) for making the enteral nutritional composition of the present invention is
More than 1mPas.
Because the nutritional ingredient of needed by human body also includes calcium ion(And other divalent cations or more high-valence cationic), and
Calcium ion(And other divalent cations or more high-valence cationic)Be not suitable for adding enteral nutritional composition simultaneously with pectin, thus
If human body needs calcium ion(And other divalent cations or more high-valence cationic), then intestines are being applied to people after being made into solution
Enteral is applied to before or after interior alimentation composition.
As the manufacture method of the enteral nutritional composition of the present invention, for example, being used as raw material fruit using commercially available above-mentioned pectin
Glue, it is set to be dissolved in pure water, so as to prepare(Concentration of pectin is 1~5 mass %'s)Aqueous pectin solution(And determine its calcium concentration),
Nutritional ingredient and possible additive are added afterwards, are eventually adding probiotics.It is 1~5 mass % in concentration of pectin in the present invention
Aqueous pectin solution calcium concentration more than 9ppm in the case of, by carrying out drop Calcium treatment to raw material pectin, so as to will equally make
It is standby to be reduced to below 9ppm into concentration of pectin for the calcium concentration in 1~5 mass % aqueous pectin solution.On the other hand, it is dense in calcium
In the case of spending for below 9ppm, the raw material pectin is selected to be dropped as workable pectin in the present invention without carrying out at calcium
Reason.
It is diluted with water using the pectin for implementing drop Calcium treatment or as the pectin that need not be dropped Calcium treatment and select, according to need
Implement heating or ferment treatment, so as to carry out degraded to pectin and incite somebody to action(It is viscous equal)Molecular weight adjusted to 10000~
35000th, it is preferably 12000~27000, the viscosity that can obtain aqueous pectin solution reaches 1~30mPas fruit of the invention
Glue solution.Or dropped after pectin can also be diluted with water in a manner of enteral nutritional composition reaches above-mentioned viscosity
Calcium treatment.It should be noted that as water used herein, preferably pure water or ion exchange water.
Embodiment
Embodiment 1
Enteric nutrient prescription:
Pectin 3%(g/ml), bifidobacterium bifidum 2,000,000,000(Colony forming unit/ml),
Wherein, contain containing nutritional agents per 100ml:Protein (1~5g) 3.4g, fat (1~5g) 3.2g, saturated fatty acid (0.1~
2g) 0.5g, it is necessary to aliphatic acid (1~5g) 1.9g carbohydrate (2~25g) 12g (monose (1~5g) 3.5g);Dietary fiber
(1~5g) 1.5g, water (adding to full dose 100ml) 89ml, vitamin A 60mg, vitamine D3 0.35mg, vitamin E 0.75mg, dimension
Raw plain K15mg, vitaminB10 .1mg, vitamin B2 0.13mg, niacinamide 0.9mg, vitamin B6 0.12mg, vitamin
B120.2mg, pantothenic acid 0.35mg, biotin 10mg, folic acid 10mg, vitamin C 4.5mg, choline 20mg, appropriate amount of water (add to full dose
100ml).Solution PH 6.4~6.8, calcium ion are no more than 0.1PPM.
Wherein, pectin is respectively in embodiment 1-1,2,3,4,5,6:Esterification degree (DE) be 10% LM and
Pectin that pectin that molecular weight is 30000, the LM that esterification degree (DE) is 5% and molecular weight are 30000,
Esterification degree (DE) be 15% LM and molecular weight be 30000 pectin, esterification degree (DE) be 25% it is low
Methoxy group pectin and pectin, the LM that esterification degree (DE) is 10% and molecular weight that molecular weight is 30000 are
The pectin that 100000 pectin, the LM that esterification degree (DE) is 10% and molecular weight are 250000.
Reference examples 1-1
Wherein pectin be esterification degree (DE) be 40% LM and molecular weight be 250000 pectin, other with reality
Apply example 1(-1).
Reference examples 1-2
Except without bifidobacterium bifidum, other with embodiment 1-1.
Reference examples 1-3
Except without bifidobacterium bifidum, other with embodiment 1-5.
Embodiment 2
Enteric nutrient prescription:2%(g/ml)Pectin, 5,000,000,000 colony forming units of bacillus coli/ml, wherein, containing nutrition
Agent contains per 100ml:Protein (1~5g) 3.4g, fat (1~5g) 3.2g, saturated fatty acid (0.1~2g) 0.5g, it is necessary to fat
Fat acid (1~5g) 1.9g carbohydrate (2~25g) 12g (monose (1~5g) 3.5g);Dietary fiber (1~5g) 1.5g, water
(add to full dose 100ml) in right amount, wherein, pectin is respectively in embodiment 2-1,2,3:Esterification degree (DE) is 7% low-methoxy
The fruit that pectin and pectin that molecular weight is 12000, the LM that esterification degree (DE) is 15% and molecular weight are 12000
The pectin that glue, the LM that esterification degree (DE) is 7% and molecular weight are 100000.Solution PH 6.4~6.8, calcium ion
No more than 0.1PPM.
Reference examples 2-1
Wherein pectin is that esterification degree (DE) is the fruit that the LM that esterification degree (DE) is 30% and molecular weight are 12000
Glue, other with embodiment 2(-1).
Reference examples 2-2
Except without bacillus coli, other with embodiment 2-1.
Reference examples 2-3
Except without bacillus coli, other with embodiment 2-3.
Embodiment 3
Enteric nutrient prescription:0.5%(g/ml)Pectin, 50,000,000,000 colony forming units of VREF/ml, wherein, containing nutritional agents
Contain per 100ml:Protein (1~5g) 3.4g, fat (1~5g) 3.2g, saturated fatty acid (0.1~2g) 0.5g, it is necessary to fat
Acid (1~5g) 1.9g carbohydrate (2~25g) 12g (monose (1~5g) 3.5g);Dietary fiber (1~5g) 1.5g, water are fitted
Measure (adding to full dose 100ml), wherein, pectin is respectively in embodiment 3-1,2,3:Esterification degree (DE) is 15% low-methoxy fruit
Pectin that glue and pectin that molecular weight is 22000, the LM that esterification degree (DE) is 30% and molecular weight are 22000,
Esterification degree (DE) is the pectin that 15% LM and molecular weight are 150000.Solution PH 6.4~6.8, calcium ion is not
More than 0.1PPM.
Reference examples 3-1
Wherein pectin is that esterification degree (DE) is the fruit that the LM that esterification degree (DE) is 60% and molecular weight are 22000
Glue, other with embodiment 3(-1).
Reference examples 3-2
Except without VREF, other with embodiment 3-1.
Reference examples 3-3
Except without VREF, other with embodiment 3-3.
Embodiment 4
Enteric nutrient prescription:10%(g/ml)Pectin, 500,000,000 colony forming units of goldbeater's skin bacillus/ml, wherein, containing nutritional agents
Contain per 100ml:Protein (1~5g) 3.4g, fat (1~5g) 3.2g, saturated fatty acid (0.1~2g) 0.5g, it is necessary to fat
Acid (1~5g) 1.9g carbohydrate (2~25g) 12g (monose (1~5g) 3.5g);Dietary fiber (1~5g) 1.5g, water are fitted
Measure (adding to full dose 100ml), wherein, pectin is respectively in embodiment 4-1,2,3:Esterification degree (DE) is 12% low-methoxy fruit
Pectin that glue and pectin that molecular weight is 35000, the LM that esterification degree (DE) is 5% and molecular weight are 35000, ester
Change degree (DE) is the pectin that 12% LM and molecular weight are 150000.Calcium ion is no more than 0.1PPM.
Reference examples 4
Wherein pectin is that esterification degree (DE) is the fruit that the LM that esterification degree (DE) is 60% and molecular weight are 150000
Glue, other with embodiment 4(-1).
Reference examples 4-2
Except without goldbeater's skin bacillus, other with embodiment 4-1.
Reference examples 4-3
Except without goldbeater's skin bacillus, other with embodiment 4-3.
Embodiment 5
Enteric nutrient prescription:1%(g/ml)Pectin, raw 500,000,000 colony forming units of the bacteroid/ml of cud, wherein, containing nutritional agents
Contain per 100ml:Protein (1~5g) 3.4g, fat (1~5g) 3.2g, saturated fatty acid (0.1~2g) 0.5g, it is necessary to fat
Acid (1~5g) 1.9g carbohydrate (2~25g) 12g (monose (1~5g) 3.5g);Dietary fiber (1~5g) 1.5g, water are fitted
Measure (adding to full dose 100ml), wherein, pectin is respectively in embodiment 5-1,2,3:Esterification degree (DE) is 8% low-methoxy fruit
Pectin that glue and pectin that molecular weight is 10000, the LM that esterification degree (DE) is 15% and molecular weight are 10000,
Esterification degree (DE) is the pectin that 8% LM and molecular weight are 150000.Solution PH 6.4~6.8, calcium ion is not
More than 0.1PPM.
Reference examples 5
Wherein pectin is that esterification degree (DE) is the fruit that the LM that esterification degree (DE) is 50% and molecular weight are 150000
Glue, other with embodiment 5(-1).
Reference examples 5-2
Except without the raw bacteroid of cud, other with embodiment 5-1.
Reference examples 5-3
Except without the raw bacteroid of cud, other with embodiment 5-3.
Embodiment 6
Embodiment 6 and its reference examples in addition to wherein probiotics is streptococcus thermophilus, other with embodiment 1 and its phase of reference examples 1
Together.
Embodiment 7
Embodiment 7 and its reference examples in addition to wherein probiotics is baby streptococcus, other with embodiment 2 and its phase of reference examples 2
Together.
Embodiment 8
Embodiment 8 and its reference examples in addition to wherein probiotics is Saccharomyces cerevisiae, other with embodiment 3 and its phase of reference examples 3
Together.
Embodiment 9
Embodiment 9 and its reference examples are in addition to wherein probiotics is mesenterium shape leukonid, and other are with embodiment 4 and its compareing
Example 4 is identical.
Embodiment 10
Embodiment 10 and its reference examples in addition to wherein probiotics is lactobacillus fermenti, other with embodiment 5 and its phase of reference examples 5
Together.
Embodiment 11
Embodiment 11 and its reference examples in addition to wherein probiotics is lactobacillus acidophilus, other with embodiment 2 and its phase of reference examples 2
Together.
Embodiment 12
Embodiment 12 and its reference examples in addition to wherein probiotics is takes Roy's Deng Shi Propionibacteriums, other with embodiment 2 and its
Reference examples 2 are identical.
Embodiment 13
Embodiment 13 and its reference examples in addition to wherein probiotics is bifidobacterium bifidum, other with embodiment 2 and its reference examples 2
It is identical.
Embodiment 14
Embodiment 14 and its reference examples in addition to wherein probiotics is lactobacillus reuteri, other with embodiment 2 and its phase of reference examples 2
Together.
Embodiment 15
In addition to wherein probiotics is aspergillus niger, other are identical with embodiment 2 and its reference examples 2 for embodiment 15 and its reference examples.
Embodiment 16
Embodiment 16 and its reference examples in addition to wherein probiotics is bifidobacterium thermophilum, other with embodiment 2 and its reference examples 2
It is identical.
Embodiment 17
Embodiment 17 and its reference examples in addition to wherein probiotics is saliva chain coccus thermophilous subspecies, other with embodiment 2 and its
Reference examples 2 are identical.
Embodiment 18
Embodiment 18 and its reference examples in addition to wherein probiotics is lactobacillus delbruockii subspecies bulgaricus, other with embodiment 2
And its reference examples 2 are identical.
Embodiment 19
It is streptococcus thermophilus, lactobacillus acidophilus, Lactobacillus casei, bifid bifid that embodiment 19 and its reference examples, which remove wherein probiotics,
Bacillus(Each 2,000,000,000 colony forming units/ml)Outside, other are identical with embodiment 2 and its reference examples 2.
Embodiment 20
It is pig bacteroid, clostridium butyricum, lactobacillus lactis, Xue Man that embodiment 20 and its reference examples, which remove wherein probiotics,
Na Shi Propionibacteriums(Each 2,000,000,000 colony forming units/ml)Outside, other are identical with embodiment 2 and its reference examples 2.
Embodiment 21
It is Pediococcus acidilactici, Lactobacillus saki, bacillus coagulans that embodiment 21 and its reference examples, which remove wherein probiotics,(Each 2,000,000,000
Colony forming unit/ml)Outside, other are identical with embodiment 2 and its reference examples 2.
Embodiment 22
It is digestion lactobacillus, staphylococcus xylosus that embodiment 22 and its reference examples, which remove wherein probiotics,(Each 4,000,000,000 Colony forming list
Position/ml)Outside, other are identical with embodiment 2 and its reference examples 2.
Test case
The stomach and intestine adverse reaction such as 1 pre- anti-diarrhea of test case or reduction diarrhoea sends rate clinical test
Data:Accept tube-fed patients 157 for medical treatment, without diarrhoea when being admitted to hospital, hepatic and renal function is without exception, patient source ICU, division of respiratory disease, god
Through internal medicine, neurosurgery.Wherein man 82, female 75, average age 45.5.Patient is randomly divided into two groups, wherein control group
7O examples, man 38, female 32, average age 45.3, seminar 87, man 44, female 43, average age 45.7 years old, patient
Sex, age, state of an illness seminar and control group indifference.
Method:Seminar uses embodiment sample, and control group is only with reference examples sample.The equal conventional therapy of patient clinical,
Two groups are continuously pumped into using nose supply bobbin, and nutrient solution is maintained at 38 DEG C or so by thermostat.According to the height of patient, body weight, year
Age, active level give nutritional support, 20 days time.Testing index:Two groups of people digest roads during nutritional support:Diarrhoea, abdomen
The number of the infected of the complication such as swollen, vomiting, which is given, to be recorded.Statistical procedures:Measurement data is represented using (X ± S), is contrasted between group
Examined using t and the contrast of two groups of rates is using examining, P≤0.05 is that difference has conspicuousness statistical significance.
It the results are shown in Table 1.
The stomach and intestine adverse reaction of 1 reference examples of table 1-1 embodiments 1 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 1-1 | 6.3 | 8.7 | 4.5 |
Embodiment 1-2 | 10.8 | 14.4 | 8.6 |
Embodiment 1-3 | 15.6 | 18.3 | 12.7 |
Embodiment 1-4 | 25.9 | 29.8 | 18.9 |
Embodiment 1-5 | 32.8 | 37.5 | 22.8 |
Embodiment 1-6 | 39.8 | 45.2 | 28.9 |
Reference examples 1-1 | 61.8 | 67.9 | 41.9 |
Reference examples 1-2 | 50.3 | 54.5 | 31.4 |
Reference examples 1-3 | 58.7 | 61.1 | 36.2 |
The stomach and intestine adverse reaction of 2 reference examples of table 1-2 embodiments 2 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 2-1 | 9.6 | 15.7 | 7.5 |
Embodiment 2-2 | 19.7 | 28.8 | 15.2 |
Embodiment 2-3 | 35.8 | 39.4 | 26.5 |
Reference examples 2-1 | 58.5 | 65.7 | 45.8 |
Reference examples 2-2 | 41.6 | 46.7 | 36.8 |
Reference examples 2-3 | 53.2 | 58.3 | 40.6 |
The stomach and intestine adverse reaction of 3 reference examples of table 1-3 embodiments 3 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 3-1 | 16.3 | 19.6 | 12.3 |
Embodiment 3-2 | 27.4 | 31.5 | 20.7 |
Embodiment 3-3 | 35.7 | 45.7 | 31.6 |
Reference examples 3-1 | 57.8 | 69.8 | 51.6 |
Reference examples 3-2 | 48.4 | 61.3 | 40.8 |
Reference examples 3-3 | 52.3 | 63.7 | 45.4 |
The stomach and intestine adverse reaction of 4 reference examples of table 1-4 embodiments 4 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 4-1 | 21.4 | 25.8 | 15.3 |
Embodiment 4-2 | 30.6 | 39.8 | 26.6 |
Embodiment 4-3 | 45.8 | 52.9 | 40.5 |
Reference examples 4-1 | 69.5 | 78.9 | 67.6 |
Reference examples 4-2 | 54.4 | 67.2 | 53.3 |
Reference examples 4-3 | 66.6 | 77.5 | 61.4 |
The stomach and intestine adverse reaction of 5 reference examples of table 1-5 embodiments 5 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 5-1 | 12.6 | 16.8 | 9.4 |
Embodiment 5-2 | 26.3 | 31.3 | 17.7 |
Embodiment 5-3 | 37.6 | 45.4 | 31.5 |
Reference examples 5-1 | 59.8 | 71.3 | 57.6 |
Reference examples 5-2 | 51.2 | 62.5 | 48.7 |
Reference examples 5-3 | 56.4 | 67.8 | 51.2 |
The stomach and intestine adverse reaction of 6 reference examples of table 1-6 embodiments 6 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 6-1 | 7.4 | 9.8 | 5.7 |
Embodiment 6-2 | 15.2 | 18.1 | 11.4 |
Embodiment 6-3 | 20.4 | 24.6 | 15.3 |
Embodiment 6-4 | 27.4 | 32.4 | 21.5 |
Embodiment 6-5 | 35.4 | 39.8 | 26.3 |
Embodiment 6-6 | 42.5 | 49.8 | 40.2 |
Reference examples 6-1 | 71.5 | 79.8 | 68.7 |
Reference examples 6-2 | 61.3 | 72.3 | 57.7 |
Reference examples 6-3 | 68.8 | 76.5 | 62.6 |
The stomach and intestine adverse reaction of 7 reference examples of table 1-7 embodiments 7 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 7-1 | 11.3 | 16.8 | 9.3 |
Embodiment 7-2 | 21.5 | 30.3 | 18.7 |
Embodiment 7-3 | 33.6 | 42.8 | 29.2 |
Reference examples 7-1 | 58.3 | 67.6 | 49.4 |
Reference examples 7-2 | 46.5 | 57.4 | 41.3 |
Reference examples 7-3 | 51.4 | 63.5 | 45.8 |
The stomach and intestine adverse reaction of 8 reference examples of table 1-8 embodiments 8 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 8-1 | 14.7 | 17.2 | 10.5 |
Embodiment 8-2 | 25.7 | 30.2 | 18.5 |
Embodiment 8-3 | 35.3 | 43.5 | 32.8 |
Reference examples 8-1 | 61.3 | 69.6 | 53.4 |
Reference examples 8-2 | 51.4 | 60.7 | 42.6 |
Reference examples 8-3 | 55.8 | 66.3 | 47.8 |
The stomach and intestine adverse reaction of 9 reference examples of table 1-9 embodiments 9 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 9-1 | 24.5 | 28.6 | 17.8 |
Embodiment 9-2 | 36.8 | 42.5 | 27.6 |
Embodiment 9-3 | 48.3 | 54.4 | 43.7 |
Reference examples 9-1 | 72.5 | 81.3 | 68.6 |
Reference examples 9-2 | 61.3 | 72.5 | 58.5 |
Reference examples 9-3 | 69.8 | 78.7 | 63.8 |
The stomach and intestine adverse reaction of 10 reference examples of table 1-10 embodiments 10 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 10-1 | 14.3 | 17.6 | 9.9 |
Embodiment 10-2 | 26.9 | 33.7 | 19.6 |
Embodiment 10-3 | 38.8 | 49.4 | 35.9 |
Reference examples 10-1 | 69.4 | 78.9 | 59.5 |
Reference examples 10-2 | 57.3 | 70.1 | 52.4 |
Reference examples 10-3 | 61.6 | 75.3 | 55.7 |
The stomach and intestine adverse reaction of 11 reference examples of table 1-11 embodiments 11 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 11-1 | 7.4 | 11.5 | 6.3 |
Embodiment 11-2 | 16.3 | 21.4 | 13.2 |
Embodiment 11-3 | 31.3 | 34.2 | 22.4 |
Reference examples 11-1 | 47.1 | 52.5 | 41.5 |
Reference examples 11-2 | 41.4 | 47.4 | 36.7 |
The stomach and intestine adverse reaction of 12 reference examples of table 1-12 embodiments 12 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 12-1 | 11.3 | 18.8 | 8.7 |
Embodiment 12-2 | 21.4 | 29.4 | 17.6 |
Embodiment 12-3 | 33.2 | 41.4 | 29.4 |
Reference examples 12-1 | 56.8 | 62.6 | 44.9 |
Reference examples 12-2 | 48.7 | 57.5 | 40.2 |
The stomach and intestine adverse reaction of 13 reference examples of table 1-13 embodiments 13 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 13-1 | 10.4 | 18.6 | 9.4 |
Embodiment 13-2 | 23.4 | 31.3 | 17.8 |
Embodiment 13-3 | 33.4 | 44.5 | 29.3 |
Reference examples 13-1 | 54.3 | 64.7 | 46.8 |
Reference examples 13-2 | 48.8 | 58.4 | 41.3 |
The stomach and intestine adverse reaction of 14 reference examples of table 1-14 embodiments 14 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 14-1 | 11.6 | 19.4 | 8.8 |
Embodiment 14-2 | 23.5 | 32.6 | 18.6 |
Embodiment 14-3 | 32.1 | 43.7 | 29.3 |
Reference examples 14-1 | 55.2 | 65.4 | 45.5 |
Reference examples 14-2 | 47.4 | 58.3 | 37.7 |
The stomach and intestine adverse reaction of 15 reference examples of table 1-15 embodiments 15 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 15-1 | 19.7 | 26.8 | 13.6 |
Embodiment 15-2 | 28.8 | 40.3 | 22.6 |
Embodiment 15-3 | 39.6 | 45.8 | 31.7 |
Reference examples 15-1 | 63.7 | 69.4 | 49.5 |
Reference examples 15-2 | 57.9 | 61.3 | 42.4 |
The stomach and intestine adverse reaction of 16 reference examples of table 1-16 embodiments 16 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 16-1 | 12.7 | 19.4 | 9.8 |
Embodiment 16-2 | 23.6 | 35.4 | 18.1 |
Embodiment 16-3 | 38.7 | 45.7 | 32.3 |
Reference examples 16-1 | 63.1 | 68.7 | 52.4 |
Reference examples 16-2 | 56.3 | 61.2 | 46.7 |
The stomach and intestine adverse reaction of 17 reference examples of table 1-17 embodiments 17 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 17-1 | 11.6 | 16.3 | 8.8 |
Embodiment 17-2 | 19.7 | 28.8 | 15.2 |
Embodiment 17-3 | 35.8 | 39.4 | 26.5 |
Reference examples 17-1 | 53.5 | 58.3 | 48.8 |
Reference examples 17-2 | 46.6 | 52.7 | 41.3 |
The stomach and intestine adverse reaction of 18 reference examples of table 1-18 embodiments 18 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 18-1 | 9.3 | 14.2 | 7.1 |
Embodiment 18-2 | 16.7 | 25.4 | 13.7 |
Embodiment 18-3 | 27.8 | 35.6 | 23.3 |
Reference examples 18-1 | 50.5 | 54.7 | 43.5 |
Reference examples 18-2 | 43.6 | 42.5 | 37.8 |
The stomach and intestine adverse reaction of 19 reference examples of table 1-19 embodiments 19 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 19-1 | 6.7 | 13.3 | 5.3 |
Embodiment 19-2 | 15.6 | 21.3 | 12.4 |
Embodiment 19-3 | 27.5 | 33.2 | 21.2 |
Reference examples 19-1 | 51.2 | 54.3 | 42.1 |
Reference examples 19-2 | 44.7 | 47.1 | 34.9 |
The stomach and intestine adverse reaction of 20 reference examples of table 1-20 embodiments 20 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 20-1 | 4.3 | 8.5 | 3.5 |
Embodiment 20-2 | 10.7 | 14.3 | 6.7 |
Embodiment 20-3 | 18.2 | 23.4 | 15.2 |
Reference examples 20-1 | 38.9 | 45.6 | 35.3 |
Reference examples 20-2 | 33.7 | 38.8 | 26.9 |
The stomach and intestine adverse reaction of 21 reference examples of table 1-21 embodiments 21 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 21-1 | 8.2 | 11.4 | 6.2 |
Embodiment 21-2 | 15.3 | 21.4 | 14.4 |
Embodiment 21-3 | 27.5 | 31.6 | 22.7 |
Reference examples 21-1 | 45.2 | 53.5 | 41.3 |
Reference examples 21-2 | 41.5 | 48.3 | 38.6 |
The stomach and intestine adverse reaction of 22 reference examples of table 1-22 embodiments 22 sends rate clinical test results
Diarrhoea(%) | Abdominal distension(%) | Vomiting(%) | |
Embodiment 22-1 | 9.1 | 15.3 | 8.2 |
Embodiment 22-2 | 18.4 | 25.6 | 14.6 |
Embodiment 22-3 | 31.2 | 36.3 | 23.8 |
Reference examples 22-1 | 50.2 | 57.1 | 42.8 |
Reference examples 22-2 | 45.1 | 52.6 | 37.3 |
Claims (10)
1. a kind of liquid enteral nutritional agent for reducing gastrointestinal side effect incidence, the Elental include one or more
Pectin is the pectin that esterification degree is 5~30% and viscosity average molecular weigh is 10000~150000, one or more probiotics and one kind
Or a variety of nutrition compositions, calcium ion is no more than 0.1PPM in the enteral nutritional composition.
2. Elental according to claim 1, wherein the pectin is esterification degree be 5~15% and viscosity average molecular weigh be
10000~150000 pectin.
3. Elental according to claim 1, wherein it is 5~15 % and viscosity average molecular weigh that the pectin, which is esterification degree,
For 10000~50000 pectin.
4. Elental according to claim 1, wherein it is 5~15 % and viscosity average molecular weigh that the pectin, which is esterification degree,
For 10000~35000 pectin.
5. Elental according to claim 1, wherein it is 5~15 % and viscosity average molecular weigh that the pectin, which is esterification degree,
For 12000~25000 pectin.
6. according to the Elental of any one in preceding claims, it is characterised in that by relative to 180~
The enteric nutrient 100mL that 220mg/100mL high concentration contains sodium adds the 10~100mL Elental, can make
The viscosity (25 DEG C) of mixed liquor is 600~10000mPas.
7. according to the Elental of any one in claim 1 to 5, it is characterised in that described pectin is sought in the body enteral
It is 0.1~10% to support the content in agent(W/w).
8. according to the Elental of any one in claim 1 to 5, it is characterised in that described probiotics is selected from sugar yeast
Belong to (Saccharomyces), Debaryomyces (Debaromyces), candida (Candida), pichia
Belong to (Pichia) and Torulopsis (Torulopsis) saccharomycete, aspergillus (Aspergillus), rhizopus
(Rhizopus), mucor (Mucor), Penicillium (Penicillium) and Torulopsis (Torulopsis) mould, and,
Bifidobacterium (Bifidobacterium), Clostridium (Clostridium), Fusobacterium
(Fusobacterium), pluton category (Melissococcus), Propionibacterium (Propionibacterium), hammer
Pseudomonas (Streptococcus), enterococcus spp (Enterococcus), lactococcus (Lactococcus), Cook Pseudomonas
(Kocuriaw), staphylococcus (Staphylococcus), Peptostreptococcus (Peptostrepococcus), gemma bar
Pseudomonas (Bacillus), Pediococcus (Pediococcus), Micrococcus (Micrococcus), Leuconostoc
(Leuconostoc), Wei Si Bordetella (Weissella), Aerococcus (Aerococcus), wine Coccus (Oenococcus)
With lactobacillus (Lactobacillus) bacterium.
9. according to the Elental of any one in claim 1 to 5, it is characterised in that described probiotics is selected from aspergillus niger
(Aspergillus niger), aspergillus oryzae (A.oryzae), bacillus coagulans (Bacillus coagulans), slow bud
Spore bacillus (B.lentus), Bacillus licheniformis (B.licheniformis), goldbeater's skin bacillus
(B.mesentericus), bacillus pumilus (B.pumilus), bacillus subtilis (B.subtilis), natto gemma bar
Bacterium (B.natto), bacteroides amylophilus (Bacteroides amylophilus), bacteroides capillosus (Bac.capillosus),
The raw bacteroid of cud (Bac.ruminocola), pig bacteroid (Bac.suis), bifidobacterium adolescentis (Bifidobacterium
Adolescentis), animal bifidobacteria (B.animalis), bifidobacterium breve (B.breve), bifidobacterium bifidum
(B.bifidum), bifidobacterium infantis (B.infantis), bifidobacterium lactis (B.lactis), bifidobacterium longum
(B.longum), bifidobacterium pseudolongum (B.pseudolongum), bifidobacterium thermophilum (B.thermophilum), Candida
Pintolepesii, clostridium butyricum (Clostridium butyricum), butterfat enterococcus (Enterococcus
Cremoris), two butanone enterococcus (E.diacetylactis), VREF (E.faecium), middle enterococcus
(E.intermedius), lactoenterococcus (E.lactis), E.muntdi, thermophilic enterococcus (E.thermophilus), large intestine
Escherich's bacillus (Escherichia coli), Kluyveromyces fragilis (Kluyveromyces fragilis), acidophilus breast
Bacillus (Lactobacillus acidophilus), digestion lactobacillus (L.alimentarius), food starch lactobacillus
(L.amylovorus), Lactobacillus crispatus (L.crispatus), short and small lactobacillus (L.brevis), Lactobacillus casei (L.case
4), lactobacillus curvatus (L.curvatus), lactobacillus cellobiosas (L.cellobiosus), Lactobacillus delbrueckii are sub-
Kind (L.delbrueckii ss.bulgaricus), Lactobacillus farciminis (L.farciminis), lactobacillus fermenti
(L.fermentum), Lactobacillus gasseri (L.gasseri), Lactobacillus helveticus (L.helveticus), lactobacillus lactis
(L.lactis), Lactobacillus plantarum (L.plantarum), Yue Shi lactobacillus (L.johnsonii), lactobacillus reuteri
(L.reuteri), Lactobacillus rhamnosus (L.rhamnosus), Lactobacillus saki (L.sakei), Lactobacillus salivarius
(L.salivarius), mesenterium shape leukonid (Leuconostoc mesenteroides), beer (harmful) piece coccus
(P.cereviseae (damnosus)), Pediococcus acidilactici (Pediococcus acidilactici), Pediococcus pentosaceus
(P.pentosaceus) Roy Deng Shi Propionibacteriums (Propionibacterium freudenreichii), Xue Man Na Shi, are taken
Propionibacterium (Prop.shermanii), Saccharomyces cerevisiae (Saccharomyces cereviseae), Staphylococcus carnosus
(Staphylococcus carnosus), staphylococcus xylosus (Staph.xylosus), baby streptococcus
(Streptococcus in fantarius), saliva chain coccus thermophilous subspecies (Strep.salivarius
Ss.thermophilus), streptococcus thermophilus (Strep.Thermophilus) and streptococcus lactis (Strep.lactis).
10. according to the Elental of any one in claim 1 to 5, it is characterised in that described probiotics is in the body intestines
The colony forming unit of every 100ml contents about 100,000,000 to about 200,000,000,000 in interior nutritional agents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710022204.9A CN107518411A (en) | 2017-01-13 | 2017-01-13 | A kind of anti-diarrhea enteral nutrition composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710022204.9A CN107518411A (en) | 2017-01-13 | 2017-01-13 | A kind of anti-diarrhea enteral nutrition composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107518411A true CN107518411A (en) | 2017-12-29 |
Family
ID=60748146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710022204.9A Pending CN107518411A (en) | 2017-01-13 | 2017-01-13 | A kind of anti-diarrhea enteral nutrition composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107518411A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109045071A (en) * | 2018-08-15 | 2018-12-21 | 珠海中科先进技术研究院有限公司 | A kind of composition that can mitigate halitosis and its application |
CN111493326A (en) * | 2020-04-28 | 2020-08-07 | 成都尚医信息科技有限公司 | Enteral nutrition food and preparation method and application thereof |
WO2023040426A1 (en) * | 2022-04-15 | 2023-03-23 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Formula of probiotics and metabolites thereof for alleviating metabolic syndromes, and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102161712A (en) * | 2011-03-04 | 2011-08-24 | 重庆莱美药业股份有限公司 | Method for preparing micromolecule pectin |
CN103974723A (en) * | 2012-07-09 | 2014-08-06 | 丘比株式会社 | Aqueous pectin solution |
JP2014193822A (en) * | 2013-03-28 | 2014-10-09 | Terumo Corp | Thickened nutritive composition |
CN104394716A (en) * | 2012-07-02 | 2015-03-04 | 荷兰联合利华有限公司 | Concentrate food composition comprising a pectin gel |
CN104936581A (en) * | 2012-08-29 | 2015-09-23 | 萨利克斯药品有限公司 | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
CN105664170A (en) * | 2016-01-23 | 2016-06-15 | 杭州吉为医疗科技有限公司 | Amidated low-ester pectin composition and method for preparing same |
-
2017
- 2017-01-13 CN CN201710022204.9A patent/CN107518411A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102161712A (en) * | 2011-03-04 | 2011-08-24 | 重庆莱美药业股份有限公司 | Method for preparing micromolecule pectin |
CN104394716A (en) * | 2012-07-02 | 2015-03-04 | 荷兰联合利华有限公司 | Concentrate food composition comprising a pectin gel |
CN103974723A (en) * | 2012-07-09 | 2014-08-06 | 丘比株式会社 | Aqueous pectin solution |
CN104936581A (en) * | 2012-08-29 | 2015-09-23 | 萨利克斯药品有限公司 | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
JP2014193822A (en) * | 2013-03-28 | 2014-10-09 | Terumo Corp | Thickened nutritive composition |
CN105664170A (en) * | 2016-01-23 | 2016-06-15 | 杭州吉为医疗科技有限公司 | Amidated low-ester pectin composition and method for preparing same |
Non-Patent Citations (1)
Title |
---|
王兴鹏等: "《肠道屏障功能障碍 基础与临床》", 30 June 2006 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109045071A (en) * | 2018-08-15 | 2018-12-21 | 珠海中科先进技术研究院有限公司 | A kind of composition that can mitigate halitosis and its application |
CN109045071B (en) * | 2018-08-15 | 2021-10-26 | 珠海中科先进技术研究院有限公司 | Composition capable of relieving halitosis and application thereof |
CN111493326A (en) * | 2020-04-28 | 2020-08-07 | 成都尚医信息科技有限公司 | Enteral nutrition food and preparation method and application thereof |
WO2023040426A1 (en) * | 2022-04-15 | 2023-03-23 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Formula of probiotics and metabolites thereof for alleviating metabolic syndromes, and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019204819B9 (en) | Compositions comprising bacterial strains | |
Lenoir-Wijnkoop et al. | Probiotic and prebiotic influence beyond the intestinal tract | |
Mountzouris et al. | Intestinal microflora of human infants and current trends for its nutritional modulation | |
Fooks et al. | Probiotics as modulators of the gut flora | |
JP2019048857A (en) | Compositions comprising bacterial strains | |
TWI744479B (en) | Compositions comprising bifidobacteria and preparation methods for the same | |
Krumbeck et al. | In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications | |
US20100166721A1 (en) | Probotic compositions and uses thereof | |
Brunser et al. | Effects of probiotic or prebiotic supplemented milk formulas on fecal microbiota composition of infants. | |
US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
CN107616984A (en) | A kind of anti-diarrhea enteral nutrition composition | |
TW201242518A (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
CN101128129A (en) | Nutritional composition with probiotics | |
WO2018175879A1 (en) | Methods of treating lactose intolerance and improving gastrointestinal health | |
AU2003282494A1 (en) | Nutritional formulations containing synbiotic substances | |
CN107518411A (en) | A kind of anti-diarrhea enteral nutrition composition | |
CN107616983A (en) | A kind of anti-diarrhea enteral nutrition composition | |
CN113164532A (en) | H5 functional Bifidobacterium longum subspecies infantis compositions and methods of use | |
JP6163619B1 (en) | Compositions and methods for improving the balance of gut microbiota | |
Niu et al. | Effect of fructooligosaccharides on the colonization of Lactobacillus rhamnosus AS 1.2466 T in the gut of mice | |
JP2022504185A (en) | Composition containing bacterial strain | |
JP4135505B2 (en) | Food for promoting colonization and growth of useful intestinal bacteria | |
JP2007131541A (en) | Agent for promoting release of growth hormone | |
JP3441756B2 (en) | Functional powdered beverage and method for producing the same | |
Taylor et al. | Functional foods and paediatric gastro-intestinal health and disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171229 |
|
RJ01 | Rejection of invention patent application after publication |